Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/6/2010

Conference Call on Thursday, May 6, 2010 at 4:30 p.m. Eastern Time

BOTHELL, WA, and VANCOUVER, May 6 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the three months ended March 31, 2010 and reviewed the Company's highlights for the first quarter of 2010.

Financial Results

Revenue for the first quarter ended March 31, 2010 was $4.7 million, of which $1.9 million consisted of partial recognition of deferred collaboration revenue representing OncoGenex's contribution to the OGX-011 Phase III development plan under our Collaboration and License Agreement with Teva Pharmaceutical Industries Ltd. ("Teva"). The remaining $2.8 million of revenue relates to OGX-011 manufacturing costs incurred by OncoGenex in the first quarter of 2010 that are reimbursable from Teva on a cash basis, and is included in amounts receivable at March 31, 2010. As of March 31, 2010, $24.6 million of the upfront payment received from Teva was included on the Company's balance sheet as deferred collaboration revenue which we are amortizing over the expected performance period of our deliverables under our agreement. We currently expect this performance period to end in the fourth quarter of 2012. In the three months ended March 31, 2009, no revenues were reco
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
2. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
3. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
4. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
5. OncoGenex Reports Third Quarter 2009 Financial Results
6. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
7. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
8. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
9. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
10. OncoGenex Reports Second Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2015)... , April 18, 2015 ... CRIS ) will be presenting data at the ... Associate of Cancer Research Annual Meeting (April 18-22 ...      (Logo: http://photos.prnewswire.com/prnh/20130418/608115 ) , ... Nicotinamide phosphoribosyltransferase (NAMPT) small molecule inhibitors program, which ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 CIO Review ... for its 20 Most Promising Pharma and Life Science ... MMIS’s MediSpend global compliance software platform for life sciences ... selected by a panel of experts and members of ... entrepreneurship. “MMIS’s MediSpend Platform has been on our radar ...
(Date:4/17/2015)... April 17, 2015  US-Australian drug discovery company, Novogen, ... of Understanding with the Feinstein Institute for Medical ... to collaborate with the objective of ... The collaboration brings together the drug discovery expertise ... of the Feinstein Institute in neurosciences and oncology. ...
(Date:4/17/2015)... Madison, WI (PRWEB) April 17, 2015 ... provide sales and marketing support for the powerful ... at the Chemical Genomics Center at the Lankenau ... LCGC’s mission is to measurably improve successful ... to HTS, by offering rare, drug-like libraries available ...
Breaking Biology Technology:Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015 2MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2
... bulbs into power-sippers, say optics researchers at the University ... bright as a 100-watt bulb consume less electricity than ... a more pleasant light than a fluorescent bulb can., ... and micro-scale structures on the surface of a regular ...
... TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) ... after consideration of potential strategic and financing alternatives, that ... and its stockholders to liquidate the Company,s assets and ... has unanimously approved a Plan of Liquidation and Dissolution ...
... COLUMBIA, Md., May 29 Martek Biosciences Corporation (Nasdaq: ... at the 8th Annual Needham Life Sciences Conference which is ... York Palace Hotel in New York City. Peter L. ... June 11, 2009, at 2:30 p.m. Eastern Time.A live audio ...
Cached Biology Technology:Regular light bulbs made super-efficient with ultra-fast laser 2Regular light bulbs made super-efficient with ultra-fast laser 3TorreyPines Therapeutics Announces its Board of Directors' Approval of Plan of Liquidation and Dissolution 2TorreyPines Therapeutics Announces its Board of Directors' Approval of Plan of Liquidation and Dissolution 3
(Date:4/10/2015)... 10, 2015 Research and Markets ... "Security Competitive Profiles - NEC" report to ... NEC will continue to supply a range of ... with a company focus on the development of a ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
(Date:4/1/2015)... 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces the second ... is underway to early access pre-order customers. ... at retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, ... was accepted at all outlets and very easy to ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... Day, World Wildlife Fund and its partners in the ... to prevent the accidental maiming and killing of marine ... by fishing nets and longlines--a problem known as bycatch--while ... solutions safeguard our living oceans," said Carter Roberts, president ...
... that showcase applications ranging from early-stage disease diagnosis to ... be well represented at the 229th National Meeting of ... in San Diego. , Founded in 1876, the ACS ... largest scientific society in the world with an international ...
... researchers chiseling away at the problem of antibiotic resistance ... main cellular target in bacteria evolves to become resistant ... leading to new experimental antibiotics that are being engineered ... problem. , Led by Thomas A. Steitz, a Howard ...
Cached Biology News:Solutions that reduce death of marine life reeled in by International Smart Gear Competition 2Solutions that reduce death of marine life reeled in by International Smart Gear Competition 3Disease diagnosis, biodefense among UH chemical research projects 2Disease diagnosis, biodefense among UH chemical research projects 3Researchers make gains in understanding antibiotic resistance 2Researchers make gains in understanding antibiotic resistance 3
... a full featured, two laser, six detector analytical ... CFlow Software, and a PC for operation and ... the capabilities of the best selling flow cytometers ... Flow Cytometer System has six detectors to capture ...
Fingerprinting II Basic software is used for analyzing fingerprint sample types (electrophoretic gels, HPLC and other chromatographic patterns, spectrophotometric and densitometric curves)....
...
Fingerprinting II cluster analysis is an optional module that adds dendrogram and phylogenetic tree construction, cluster and group significance, and congruence of techniques functions to the Fingerp...
Biology Products: